Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · IEX Real-Time Price · USD
105.25
-0.21 (-0.20%)
At close: May 31, 2024, 4:00 PM
105.15
-0.10 (-0.10%)
After-hours: May 31, 2024, 6:56 PM EDT
Jazz Pharmaceuticals Employees
Jazz Pharmaceuticals had 2,800 employees on December 31, 2023. The number of employees did not change compared to the previous year.
Employees
2,800
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$1,372,634
Profits / Employee
$118,141
Market Cap
6.63B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2,800 | 0 | - |
Dec 31, 2022 | 2,800 | -400 | -12.50% |
Dec 31, 2021 | 3,200 | 1,260 | 64.95% |
Dec 31, 2020 | 1,940 | 320 | 19.75% |
Dec 31, 2019 | 1,620 | 260 | 19.12% |
Dec 31, 2018 | 1,360 | 150 | 12.40% |
Dec 31, 2017 | 1,210 | 170 | 16.35% |
Dec 31, 2016 | 1,040 | 130 | 14.29% |
Dec 31, 2015 | 910 | 40 | 4.60% |
Dec 31, 2014 | 870 | 60 | 7.41% |
Dec 31, 2013 | 810 | 200 | 32.79% |
Dec 31, 2012 | 610 | 179 | 41.53% |
Dec 31, 2011 | 431 | 189 | 78.10% |
Dec 31, 2010 | 242 | 14 | 6.14% |
Dec 31, 2009 | 228 | 12 | 5.56% |
Dec 31, 2008 | 216 | -193 | -47.19% |
Dec 31, 2007 | 409 | 224 | 121.08% |
Dec 31, 2007 | 185 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
The Ensign Group | 35,300 |
Acadia Healthcare Company | 23,500 |
Masimo | 3,800 |
HealthEquity | 3,150 |
Legend Biotech | 1,826 |
Exelixis | 1,310 |
Blueprint Medicines | 655 |
Intra-Cellular Therapies | 610 |
JAZZ News
- 1 day ago - Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024 - PRNewsWire
- 3 days ago - Jazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024 - PRNewsWire
- 4 days ago - Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences - PRNewsWire
- 4 days ago - Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer - PRNewsWire
- 11 days ago - Jazz Pharmaceuticals Announces Collaboration with Life Science Cares to Improve the Wellbeing of Under Resourced Communities through Employee Volunteerism - PRNewsWire
- 4 weeks ago - Jazz Pharmaceuticals to Participate in the BofA Securities 2024 Health Care Conference - PRNewsWire
- 4 weeks ago - Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results and Affirms 2024 Financial Guidance - PRNewsWire
- 5 weeks ago - Jazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024 - PRNewsWire